The rapid evolution of HIV under antiretroviral pressure necessitates ongoing surveillance of drug resistance mutations. Next-generation sequencing (NGS) has emerged as a transformative technology in ...
SAN FRANCISCO, Nov. 13, 2025 /PRNewswire/ -- The global next-generation sequencing market size is anticipated to reach USD 42.25 billion by 2033, growing at a CAGR of 18.0% from 2025 to 2033. The next ...
Next-generation sequencing (NGS) has increased the speed, scale, throughput, and accessibility of sequencing, greatly accelerating genomic research. This progress has been aided by the development of ...
Pattern of resistance on first-line EGFR-directed therapy in EGFR-positive metastatic non-small cell lung cancer. Utilizing TP53 mutation status and initial disease burden at presentation to ...
Advances in next-generation sequencing (NGS) have propelled genomics research to new heights. With the introduction of new sequencing platforms such as Element Biosciences’ AVITI and Ultima Genomics’ ...
Life sciences and diagnostics company Revvity has had a busy couple of years, playing a major role in the next-generation sequencing-based screening of newborns to better enable healthcare ...
Next-generation sequencing (NGS) has revolutionized genomics, empowering scientists with a powerful tool to sequence millions of DNA fragments at once. This transformative technology has increased the ...
Clinical study on the assessment of first-line drug efficacy in advanced gastric cancer by monitoring circulating tumor cells through a self-developed microfluidic chip. Prognostic value of ...
NGS continually delivers breakthroughs in genomics, and to do so, it relies on the crucial step of sample preparation. Complex and expensive workflows are significant challenges. At Revvity, we are ...
Please provide your email address to receive an email when new articles are posted on . Real-world data show that only about 30% to 40% of patients with the most common cancers receive NGS testing.
A major pitfall is that most next-generation sequencing assays fail to detect the underlying genetic mechanisms of SMARCB1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results